STOCK TITAN

Investor group (NASDAQ: MRVI) reports 7.23% Maravai LifeSciences stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Maravai LifeSciences Holdings, Inc. received an updated ownership disclosure from an investor group filing an amended Schedule 13G. The group reports beneficial ownership of 10,486,451 Class A common shares, representing 7.23% of the class as of the event date.

The filing lists Hudson View entities with sole voting and dispositive power over 4,979,802 shares each, JD Squared entities with 3,000,000 shares each, and individuals including Stuart Feldman with 7,979,802 shares. The group certifies the shares were not acquired to change or influence control of Maravai.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Hudson View Holdings LLC
Signature:/s/ Jeffrey Goldberg
Name/Title:Authorized Signatory
Date:02/13/2026
Hudson View Capital LLC
Signature:/s/ Jeffrey Goldberg
Name/Title:Authorized Signatory
Date:02/13/2026
JD Squared Holdings II LLC
Signature:/s/ Jeffrey Goldberg
Name/Title:Authorized Signatory
Date:02/13/2026
JD Squared Capital II LLC
Signature:/s/ Jeffrey Goldberg
Name/Title:Authorized Signatory
Date:02/13/2026
Stuart Feldman
Signature:/s/ Joseph Brucchieri
Name/Title:Attorney-in-fact
Date:02/13/2026
Matthew Barkoff
Signature:/s/ Matthew Barkoff
Name/Title:Individual
Date:02/13/2026
Joshua Wool
Signature:/s/ Joshua Wool
Name/Title:Individual
Date:02/13/2026
Exhibit Information

99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Schedule 13G in respect of Maravai LifeSciences Holdings, Inc. filed on May 29, 2025) 99.2 Power of Attorney (incorporated by reference to Exhibit 99.2 to the Schedule 13G in respect of Mural Oncology plc filed on May 14, 2025)

FAQ

What percentage of Maravai LifeSciences (MRVI) shares does this investor group report owning?

The investor group reports beneficial ownership of 7.23% of Maravai LifeSciences Class A common stock. This corresponds to 10,486,451 shares as disclosed in the Schedule 13G/A ownership section.

Which entities are part of the investor group in the Maravai (MRVI) Schedule 13G/A?

The filing lists Hudson View Holdings LLC, Hudson View Capital LLC, JD Squared Holdings II LLC, JD Squared Capital II LLC, and individuals Stuart Feldman, Matthew Barkoff, and Joshua Wool as members of the group.

How many Maravai (MRVI) shares does Stuart Feldman beneficially own according to the filing?

Stuart Feldman is reported as beneficially owning 7,979,802 Maravai Class A shares. He has sole voting and sole dispositive power over this amount, as reflected in the individual ownership table.

Does the Maravai (MRVI) investor group seek to influence control of the company?

The group explicitly certifies the securities were not acquired and are not held for the purpose of changing or influencing control of Maravai. They state holdings are not part of any control-seeking transaction.

What are the holdings of the Hudson View entities in Maravai LifeSciences (MRVI)?

Both Hudson View Holdings LLC and Hudson View Capital LLC report sole voting and dispositive power over 4,979,802 Maravai Class A shares each, corresponding to 3.43% of the class for each reporting person.

What stake do the JD Squared entities report in Maravai LifeSciences (MRVI)?

JD Squared Holdings II LLC and JD Squared Capital II LLC each report beneficial ownership of 3,000,000 Maravai Class A shares. For each entity, this stake represents 2.07% of the outstanding Class A common stock.
Maravai Lifesciences Holdings, Inc.

NASDAQ:MRVI

MRVI Rankings

MRVI Latest News

MRVI Latest SEC Filings

MRVI Stock Data

446.67M
106.39M
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO